Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer

Pathologie Biologie

Volumn 61, Issue 6, 2013, Pages 273-276

  Marchoudi, N ^a,b   Amrani Hassani Joutei, H ^c,d   Jouali, F ^a,b   Fekkak, J ^b   Rhaissi, H ^a  

^a FACULTÉ DES SCIENCES BEN M SIK   (Morocco)

^b Centre spécialisé des analyses médicales Anoual Casablanca   (Morocco)

^c HASSAN II UNIVERSITY OF CASABLANCA   (Morocco)

^d Institut Pasteur du Maroc   (Morocco)

Author keywords

BRAF mutation; Colorectal cancer; KRAS mutation

Indexed keywords

ALANINE; ARGININE; ASPARTIC ACID; B RAF KINASE; CYSTEINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GLYCINE; K RAS PROTEIN; MUTANT PROTEIN; SERINE; VALINE;

ADULT; ADVANCED CANCER; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CODON; COLORECTAL CANCER; CONTROLLED STUDY; ETHNIC GROUP; EXON; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MOROCCAN; ONCOGENE; ONCOGENE BRAF; ONCOGENE K RAS; PHASE TRANSITION; TREATMENT RESPONSE; TUMOR LOCALIZATION; VERY ELDERLY;

BRAF MUTATION; CANCER COLORECTAL; COLORECTAL CANCER; KRAS MUTATION; MUTATION DU BRAF; MUTATION DU KRAS;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE FREQUENCY; HUMANS; MALE; MIDDLE AGED; MOROCCO; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84888883391     PISSN: 03698114     EISSN: 17683114     Source Type: Journal    
DOI: 10.1016/j.patbio.2013.05.004     Document Type: Article

References (25)

1. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
2. Di Nicolantino F., et al. Wild Type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26(35):5705-5712.
3. Hoshino R., Chatani Y., Yamori T., et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999, 18:813-822.
4. Wang L., Cunningham J.M., Winters J.L., et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003, 63:5209-5212.
5. Karnoub A.E., Weinberg R.A. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008, 9:517-531.
6. Van Cutsem E., Kohne C.H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408-1417.
7. Andreyev H.J., Norman A.R., Cunningham D., et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001, 85:692-696.
8. Wan P.T., Garnett M.J., Roe S.M., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867.
9. Yuen S.T., Davies H., Chan T.L., et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002, 62:6451-6455.
10. Storm S.M., Rapp U.R. Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors. Toxicol Lett 1993, 67:201-210.
11. Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B., Velculescu V.E. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002, 418:934.
12. Lang A.H., Drexel H., Geller-Rhomberg S., et al. Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF. J Mol Diagn 2011, 13(1):24-26.
13. Amado R.G., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Cancer J Clin Oncol 2008, 26:1626-1634.
14. De Roock W., et al. KRAS mutation status and early radiological response predict survival in colorectal cancer treated with Cetuximab. Ann Oncol 2008, 19:508-515.
15. Van Krieken J.H.J.M., et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008, 453(5):417-431.
16. Bos J.L., et al. Prevalence of RAS mutations in human colorectal cancers. Nature 1987, 327:293-297.
17. Di Fiore F., et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007, 96:1166-1169.
18. Gnanasampanthan G., Elsaleh H., McCaul K., Iacopetta B. Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes C colorectal cancer. J Pathol 2001, 195:543-548.
19. Neuman J., Kirchner T., Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 2009, 205(12):858-862.
20. Topal M.D. DNA repair, oncogenes and carcinogenesis. Carcinogenesis 1988, 9:691-696.
21. Zarbl H., Sukumar S., Arthur A.V., Martin-Zanca D., Barbacid M. Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N- methylurea during initiation of mammary carcinogenesis in rats. Nature 1985, 315:382-385.
22. Davies H., et al. Mutations of the BRAF gene in human cancer. Nature 2001, 417:949-954.
23. Laurent-Puig P., et al. Analysis of PTEN, BRAF and EGFR status in determining benefit from cetuximab therapy in wild type KRAS metastatic colon cancer. J Clin Oncol 2009, 27(35):5924-5931.
24. Linardou H., et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced colorectal cancer. Lancet Oncol 2008, 9(10):962-972.
25. Roth A.D., et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2009, 28(3):466-474.